Free Trial

Hologic (HOLX) Stock Forecast & Price Target

Hologic logo
$77.54 -1.64 (-2.07%)
(As of 05:20 PM ET)

Hologic - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
8

Based on 12 Wall Street analysts who have issued ratings for Hologic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 4 have given a hold rating, and 8 have given a buy rating for HOLX.

Consensus Price Target

$89.91
15.95% Upside
According to the 12 analysts' twelve-month price targets for Hologic, the average price target is $89.91. The highest price target for HOLX is $95.00, while the lowest price target for HOLX is $82.00. The average price target represents a forecasted upside of 15.95% from the current price of $77.54.
Get the Latest News and Ratings for HOLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hologic and its competitors.

Sign Up

HOLX Analyst Ratings Over Time

TypeCurrent Forecast
11/15/23 to 11/14/24
1 Month Ago
10/16/23 to 10/15/24
3 Months Ago
8/17/23 to 8/16/24
1 Year Ago
11/15/22 to 11/15/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$89.91$87.50$87.60$87.36
Forecasted Upside15.95% Upside7.15% Upside7.51% Upside21.32% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

HOLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HOLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Hologic Stock vs. The Competition

TypeHologicMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside15.39% Upside25,253.10% Upside8.54% Upside
News Sentiment Rating
Positive News

See Recent HOLX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/5/2024UBS Group
4 of 5 stars
 Boost TargetNeutral ➝ Neutral$84.00 ➝ $90.00+12.60%
11/5/2024Mizuho
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$90.00 ➝ $87.00+8.85%
11/5/2024Raymond James
4 of 5 stars
 Boost TargetOutperform ➝ Outperform$93.00 ➝ $95.00+18.85%
11/5/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$86.00 ➝ $89.00+11.72%
11/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$92.00 ➝ $94.00+17.79%
10/15/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$90.00 ➝ $90.00+10.27%
10/8/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$95.00 ➝ $90.00+12.67%
10/1/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetIn-Line ➝ In-Line$78.00 ➝ $82.00+1.61%
10/1/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$95.00 ➝ $85.00+4.35%
7/30/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Carrico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$92.00 ➝ $92.00+12.81%
5/9/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$89.00 ➝ $95.00+24.48%
2/2/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
11/13/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$86.00 ➝ $82.00+14.22%
8/1/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$94.00 ➝ $86.00+8.29%
2/2/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$86.00 ➝ $95.00+14.76%
1/10/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$75.00 ➝ $80.00+0.26%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:38 PM ET.


Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, November 2, 2024. Please send any questions or comments about these Hologic pros and cons to contact@marketbeat.com.

Hologic
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Hologic, Inc.:

  • Hologic, Inc. has seen consistent insider selling in the last three months, indicating confidence in the company's future prospects.
  • Institutional investors have been increasing their stakes in Hologic, Inc., with notable additions from reputable firms like Bank of Nova Scotia and California State Teachers Retirement System.
  • Recent hedge fund activity has shown a positive sentiment towards Hologic, Inc., with notable increases in holdings by firms like Massmutual Trust Co. FSB ADV and Graypoint LLC.
  • Hologic, Inc. operates in the women's health sector, a niche market with high growth potential due to increasing awareness and demand for healthcare services tailored to women.
  • The current stock price of Hologic, Inc. is at a reasonable valuation compared to its industry peers, presenting a potential buying opportunity for investors.

Hologic
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Hologic, Inc. for these reasons:

  • Hologic, Inc. has a relatively low percentage of insider ownership, which may raise concerns about alignment of interests between management and shareholders.
  • While institutional investors have been increasing their stakes, the high concentration of ownership by institutions (94.73%) could lead to volatility in the stock price based on their trading decisions.
  • Despite positive hedge fund activity, increased competition in the women's health sector could impact Hologic, Inc.'s market share and profitability in the future.
  • The medical equipment industry is subject to regulatory changes and technological advancements, posing risks to Hologic, Inc.'s product development and market positioning.
  • Investing in Hologic, Inc. involves exposure to healthcare sector risks, including regulatory uncertainties, reimbursement challenges, and clinical trial outcomes that could affect the company's financial performance.

HOLX Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Hologic is $89.91, with a high forecast of $95.00 and a low forecast of $82.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HOLX shares.

According to analysts, Hologic's stock has a predicted upside of 15.95% based on their 12-month stock forecasts.

Over the previous 90 days, Hologic's stock had 1 downgrade by analysts.

Hologic has been rated by research analysts at Citigroup, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Mizuho, Needham & Company LLC, Raymond James, Royal Bank of Canada, and UBS Group in the past 90 days.

Analysts like Hologic less than other "medical" companies. The consensus rating score for Hologic is 2.67 while the average consensus rating score for "medical" companies is 2.80. Learn more on how HOLX compares to other companies.


This page (NASDAQ:HOLX) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners